Local view for "https://dbmi-icode-01.dbmi.pitt.edu/dikb/resource/Evidence/375"

Predicate	Value (sorted: none)
rdf:type	?:Evidence
rdf:type	?:Item
rdfs:label	"evidence_1656"
?:Evidence_type	?:Non_Tracable_Statement
?:Evidence_enzyme_system	""
dc:creator	"boycer"
dc:date	"09/24/2009 15:39:40"
?:content	"The FDA recommends warfarin as a preferred CYP2D6 substrate for in vivo studies in it most recent guidance document (See Table 2, p. 19) and expressly mentions that S-warfarin should be target of chemical analysis on 9, 1st paragraph."
rdfs:seeAlso	?:FDA-Guidance-Drug-Interaction-Studies%E2%80%93Study%20Design-Data-Analysis-and-Implications-2006.pdf

All properties reside in the graph file:///home/swish/src/ClioPatria/guidelines/dikb.ttl

The resource appears as object in one triple:

{ S-warfarin_primary_total_clearance_enzyme_cyp2c9, <http://purl.org/swan/1.2/swan-commons#citesAsSupportingEvidence>, evidence_1656 }

Context graph